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Abstract
Background: Recent studies have identified several single nucleotide polymorphisms (SNPs) in the population that are
associated with variations in the risks of many different diseases including cancers such as breast, prostate and colorectal.
For ovarian cancer, the known highly penetrant susceptibility genes (BRCA1 and BRCA2) are probably responsible for only
40% of the excess familial ovarian cancer risks, suggesting that other susceptibility genes of lower penetrance exist.
Methods:We have taken a candidate approach to identifying moderate risk susceptibility alleles for ovarian cancer. To date,
we have genotyped 340 SNPs from 94 candidate genes or regions, in up to 1,491 invasive epithelial ovarian cancer cases
and 3,145 unaffected controls from three different population based studies from the UK, Denmark and USA.
Results: After adjusting for population stratification by genomic control, 18 SNPs (5.3%) were significant at the 5% level, and
5 SNPs (1.5%) were significant at the 1% level. The most significant association was for the SNP rs2107425, located on
chromosome 11p15.5, which has previously been identified as a susceptibility allele for breast cancer from a genome wide
association study (P-trend = 0.0012). When SNPs/genes were stratified into 7 different pathways or groups of validation
SNPs, the breast cancer associated SNPs were the only group of SNPs that were significantly associated with ovarian cancer
risk (P-heterogeneity = 0.0003; P-trend= 0.0028; adjusted (for population stratification) P-trend= 0.006). We did not find
statistically significant associations when the combined data for all SNPs were analysed using an admixture maximum
likelihood (AML) experiment-wise test for association (P-heterogeneity = 0.051; P-trend= 0.068).
Conclusion: These data suggest that a proportion of the SNPs we evaluated were associated with ovarian cancer risk, but
that the effect sizes were too small to detect associations with individual SNPs.
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Introduction
One of the strongest risk factors for invasive epithelial ovarian
cancer is a family history of the disease; a woman with a single first-
degree relative diagnosed with ovarian cancer has a 2–3 fold
increased risk [1]. Familial aggregation of cancer could be due to
either a sharing of environmental or lifestyle risk factors within
families, or through the inheritance of genetic risk factors. The higher
rates of cancer in monozoygotic twins, compared with dizygotic twins
or other siblings of individuals with cancer, suggests that genetic
factors play a greater role [2].
Germline mutations in the high penetrance genes BRCA1 and
BRCA2 are responsible for the vast majority of families containing
multiple cases of ovarian cancer (.3 cases) and two or more cases
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of breast and ovarian cancer [3–5]. Other highly penetrant genes
may exist, but these are likely to be rare and account for only a
small fraction of the excess familial risk. The risk of ovarian cancer
in first-degree relatives of ovarian cancer patients compared to the
population risk is estimated to be about 2.4 [6]. Approximately
60% of this familial relative risk is not accounted for by the known
high risk loci [7]. This remaining risk is likely to be caused by a
combination of common low penetrance genes (the common
variant: common disease hypothesis) and/or rare variants of
moderate penetrance [8].
Genetic association studies, which compare the frequencies of
common genetic variants between cases and unaffected controls,
have become the preferred approach to look for low penetrance
cancer susceptibility genes. Candidate gene studies have focused
on common variants in genes that may play a role in cancer (e.g.
cell cycle control; DNA damage repair and response; proliferation
and apoptosis) with some success [9–14]. However, they have
often been limited by small sample sizes, which reduce the power
to detect associations at very stringent levels of significance.
Consortium based studies have been used to increase the samples
size and attempt to validate preliminary results [15–19]. More
recently, genome-wide association studies, an approach that
compares the frequency of hundreds of thousands of SNPs
distributed evenly throughout the genome, have been successful in
identifying low penetrance susceptibility variants for breast,
colorectal and prostate cancers [20–25]. There are, as yet, no
published genome-wide association studies for ovarian cancer.
Therefore, we have continued to take a candidate gene approach
to identify ovarian cancer susceptibility markers. We have mainly
used an empirical approach, in which a minimal set of ’’tagging’’
single nucleotide polymorphisms (SNPs) that efficiently capture all
the common genetic variation in a gene, to find genetic
susceptibility markers for ovarian cancer [11–14]. The candidate
genes in this study were involved in several cancer related
pathways; but we have also analysed candidate SNPs from the
Ovarian Cancer Association Consortium (OCAC) validation
studies and from two recently completed breast cancer genome
wide association studies [20,21].
The analysis of genetic association studies inevitably involves a
large number of statistical tests, and there has been much debate
about how to correct for multiple hypothesis testing. This has
usually been considered a hypothesis-testing problem in which the
aim is to control the overall ‘‘experiment-wise’’ type I error. The
null hypothesis is that there is no association between any of the
SNPs being tested with disease, and the aim is to test whether this
global null hypothesis of no association can be rejected. A variety
of methods have been proposed to test the global null hypothesis
[26–30]. One of these, the admixture maximum likelihood (AML)
test, simultaneously estimates the proportion of associated SNPs
and their typical effect size. The power of the AML test has been
found to be similar to or better than all other tests (rank truncated
product, unrestricted maximum likelihood, restricted space
maximum likelihood, most significant SNP, Global x2, Best subset
x2) across a wide range of scenarios for the alternative hypothesis
[31]. The simple Bonferroni correction performed best only when
the number of associated SNPs was small (typically #3 or ,5% of
SNPs tested, whichever is smaller).
The AML method has been used to evaluate the overall
evidence of association between 710 common variants in 117
candidate genes and breast cancer risk [32]. The results of this
study showed that a proportion of SNPs in these candidate genes
were associated with breast cancer risk, but that the effects of
individual SNPs were likely to be small. In the current study, we
use the AML method to evaluate data from 12 previous studies [9–
19] for global evidence of associations between the risk of invasive
epithelial ovarian cancer and 340 SNPs from 84 genes and 10
different chromosomal regions – SNPs in these regions are not
within known genes or open reading frames. Three population-
based studies comprising approximately 1,500 cases of invasive
epithelial ovarian cancer and 3,100 unaffected controls were
analysed.
Materials and Methods
Ethics Statement
Ethics committee approval was obtained for the collection and
genetic analysis of all samples, and an informed written consent
was obtained from all participants. Ethics approvals were granted
by; the Danish Ethical Committees of Copenhagen and Freder-
iksberg (MALOVA), Anglia and Oxford Multi Centre Research
Ethics Committee (SEARCH) and the Institutional Review Boards
of Stanford University School of Medicine and Roswell Park
Cancer Institute (GEOCS).
Study individuals
Three population-based ovarian cancer case-control series were
used in this research [9]: MALOVA (446 cases, 1,221 controls)
from Denmark, SEARCH (719 cases, 855 controls) from the UK,
and GEOCS (325 cases, 429 controls) from the USA. The case
collection for MALOVA ran from 1994 to 1999 in Danish
counties with a gynaecological hospital department. Cases were
women diagnosed with invasive epithelial ovarian cancer aged 30–
80 years. Controls were age-matched (within 3 years) and were
randomly drawn from Danish born women in the study area by
means of the computerized Danish Central Population Register.
SEARCH began recruitment in 1998 and covers the regions
served by the East Anglian and West Midlands cancer registries in
the UK. Eligible women were those diagnosed since 1991 with
invasive epithelial ovarian cancer under the age of 70 years.
Controls, aged 45–74 years, from the same geographical region as
the cases, were from the Norfolk constituent of the European
Prospective Investigation of Cancer (EPIC) cohort. The Genetic
Epidemiology Ovarian Cancer Study (GEOCS, formerly known
as FROC) recruited participants from 6 counties in the San
Francisco Bay area USA from 1997 to 2002. Patients, aged
between 23–64 years, with invasive epithelial ovarian cancer were
identified via rapid case ascertainment through the Greater Bay
Area Cancer Registry operated by the Northern California Cancer
Centre as part of the SEER Program. Control women were
identified through random-digit dial and were frequency-matched
to cases on race/ethnicity and five-year age group. Cases in
MALOVA were collected prospectively, GEOCS retrospectively
and SEARCH both prospectively and retrospectively. For all three
studies, DNA samples were extracted from blood by Whatman
International. Further details of these studies have been published
previously [9–14].
Gene and tag SNP selection
Candidate gene selection was primarily based on biological
pathways that are predicted to be involved in ovarian carcino-
genesis. The major pathways evaluated were DNA double strand
break repair, cell cycle control and DNA mismatch repair (MMR).
We also analysed several known or candidate tumour suppressor
genes and oncogenes for ovarian cancer and a series of genes that
we identified from the analysis of an in vitro functional model of
ovarian cancer [33]. Finally, we analysed SNPs that have
previously shown weak evidence of association with ovarian
cancer risks and SNPs that are known to be associated with breast
SNP Analysis of Ovarian Cancer
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cancer risk. The pathways, genes and SNPs analysed are listed in
Table S1. Further details on some of these genes and SNPs, and
their association with ovarian cancer have been published [9–14].
For most genes, a tagging SNP approach was used to select
known common variants. Haploview and Tagger were used for
the selection of common variants from the reference CEPH
genotypes. The approach involved the tagging of common SNPs
with a tagging SNP (tSNP) with a minimum r2 of 0.8. If a SNP was
poorly correlated with other SNPs, then 2- or 3-marker haplotypes
were used, (an approach called ‘‘aggressive tagging’’), if the
haplotypes tagged the SNP(s) with a minimum r2 of 0.8. SNP
tagging reduces the number of SNPs that require genotyping in
association studies. The MMR gene study was completed before
tagging SNP approaches were widely used due to the lack of
available information from the International HapMap Project;
and so we analysed SNPs of varying frequencies selected from
public databases such as the dbSNP database (http://www.ncbi.
nlm.nih.gov/SNP) and from the NIEHS Environmental Genome
Project (EGP) (http://egp.gs.washington.edu/) [12].
The genotyping methods used in these studies have been
described previously (9–14). All assays were carried out in 384-well
plates and included 12 duplicate samples per plate (3%).
Genotypes were excluded if duplicate concordance rates for a
study were ,98%. Plates also included non-template negative test
controls. Finally genotypes were excluded from the analysis if call
rates were ,90% per plate. The average call rates for these SNP
were 94% in cases and 96% in controls. A list of the SNPs
genotyped in this study is provided in Table S1.
Statistical methods
Associations between invasive epithelial ovarian cancer and
each SNP were assessed using two tests; the one-degree of freedom
Cochran–Armitage trend test and the general two-degrees of
freedom x2 test (heterogeneity test). Both tests were stratified by
study to account for any differences within the sample sets. The
overall evidence for an excess of associations between common
variants and ovarian cancer risk was evaluated with the AML
method, which is described in detail in Tyrer et al [31]. Briefly, the
AML method formulates the alternative hypothesis in terms of the
probability (a) that a given SNP is associated with disease and a
measured effect size. When a SNP is associated with disease, the
calculated x2 statistic will be distributed, asymptotically, as a non-
central x2 distribution with the usual degrees of freedom and a
non-centrality parameter g. The non-centrality parameter is a
measure of the size of effect of the SNP, and is closely related to
the contribution of the SNP to the genetic variance of the trait.
The non-centrality parameter was assumed to be the same for all
SNPs to make the model more parsimonious. This was an
approximation but improves power if the non-centrality parameter
is roughly the same for associated SNPs as fewer parameters have
to be optimized. If g is assumed to be the same for each associated
SNP, then both a and g can be estimated by maximum likelihood,
and a test of the null hypothesis can then be obtained as a
likelihood ratio test. In instances such as this, where some SNPs
were correlated, pseudo-maximum likelihood estimates can still be
produced by the same procedure, as if the SNPs were
independent. Therefore the pseudo-maximum-likelihood method
was applied to account for LD between SNPs. Simulation can
subsequently be used to establish the statistical significance of the
test. We applied the AML method using both the trend and
heterogeneity tests. All analyses were adjusted for cryptic
population stratification using the method described by Devlin et
al [32,33]. Genotyping data from 280 randomly selected, unlinked
SNPs were used to adjust for population stratification using the
genomic control method [33]. These genotyping data were from
cases and controls derived from a breast cancer genome-wide
association study [20]. The inflation test statistic we used was
based on the inflation seen in genomic control samples for the
breast cancer study and was chosen to be slightly higher than the
estimated inflation as a ‘‘conservative’’ correction. We therefore
adjusted the p-trend by 10% (1.1) and p-heterogeneity by 5%
(1.05) as a means of conservatively allowing for any cryptic
population stratification. Statistical significance is at the 5% level
unless stated otherwise.
Results
We have genotyped 340 SNPs in up to 1,491 invasive epithelial
ovarian cancer cases and 3,145 unaffected controls from three
different population based studies from the UK, Denmark and
USA. SNPs were either tagging SNPs located in 84 candidate
genes from pathways implicated in ovarian cancer development,
or candidate SNPs located in 10 different regions on chromosomes
2, 3, 5, 8, 11, 12 and 17 that had been chosen for validation by the
Ovarian Cancer Association Consortium (OCAC) or had been
identified in a breast cancer genome-wide association study [9–
21]. Genotype frequencies for these SNPs in cases and controls are
given in Table S1.
Using the trend test for association, 22 SNPs (6.5%) were
significant at the 5% level, and 5 SNPs (1.5%) were significant at
the 1% level. After adjusting for population stratification by
genomic control, 18 SNPs (5.3%) were significant at the 5% level,
and 5 SNPs (1.5%) were significant at the 1% level (Table 1). The
test results for every SNP are given in Table S2. Figure 1 illustrates
the results of the univariate trend test shown as a quantile-quantile
(Q-Q) plot, in which the ordered test statistics are plotted against
the expected statistics given the rank. The Q–Q plot follows the
line of equivalence for the first 240 SNPs and then starts to deviate,
as would be expected if a modest proportion of SNPs were
associated with disease.
Of the 22 SNPs that were significant at the 5% level, three were
SNPs that had been selected because of their association with
breast cancer in genome wide association studies (of 16 in that
group), eight were from the cell-cycle control pathway (of 101),
two were from the DNA mismatch repair pathway (of 43), one was
from the DNA double strand break repair pathway (of 28), two
were from the MMCT-18 (functional candidate gene) group (of
63) and five were from the OCAC group of SNPs (of 55).
However, no single SNP reached a level of significance to provide
definitive evidence of association - the most significant association
was for a breast cancer associated SNP, rs2107425, located on
chromosome 11p15.5 (unadjusted P-trend= 0.0012). The SNP
was still significantly associated with ovarian cancer risk after
adjustment for population stratification (P-trend= 0.0019).
Table 2 shows the results of the AML experiment-wise tests
summarised for the complete set of SNPs categorised according to
functional group, biological pathway or genotyping group. The
test for overall association was significant for the breast cancer
associated group of SNPs identified by genome wide association
studies (P-het. = 0.0003, P-trend= 0.0028; adjusted P-
trend= 0.0059). No other group of SNPs was significant. When
all the data were combined, the AML experiment-wise test for
association was not significant for both the heterogeneity test
(P=0.051) and the trend test (P=0.068). This suggests that,
although not statistically significant, there is a trend towards a
proportion of the SNPs evaluated being associated with disease
and that the effect sizes were too small to detect for individual
SNPs.
SNP Analysis of Ovarian Cancer
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Discussion
There are many studies in the published literature describing a
candidate SNP/gene approach to search for common, germline
genetic variants associated with epithelial ovarian cancer risk.
These studies provide some evidence of association with disease
risk for some SNPs [9–19,34,35]. In the current study, we have
used data from 12 of these studies from three population based
ovarian cancer case-control series. In total, 340 SNPs in 94 genes
or regions were analysed in approximately 1,500 cases and 3,100
controls. Based on results of univariate analyses, we found
borderline evidence of association for several SNPs, but no
susceptibility alleles significant at the P,0.00001 level, which has
been suggested as the threshold for candidate gene studies [36]. In
the current analysis, the most significant SNPs identified in this
dataset were rs2107425 on chr 11p15.5 (P= 0.0012) and
rs3817198 in LSP1 (P= 0.0016), both of which have been
identified as susceptibility alleles for breast cancer, and
rs9322336, which is located in the oestrogen receptor (ESR1)
gene (P= 0.0013). All three SNPs remained significant after
adjusting for population stratification.
Even though none of the associations we found were highly
statistically significant, we cannot rule out that one or more of these
SNPs, or alternative SNPs within the candidate genes we analysed
were associated with ovarian cancer risk. The combined sample size
from the three case-control studies did not have sufficient statistical
power to detect associations with highly stringent levels of statistical
significance. For individual variants, the statistical power of the
study depends on the minor allele frequency, the risks conferred,
and the genetic model. For this study, we had 97% power at the 5%
significance level to detect a co-dominant allele with a minor allele
frequency of 0.3 that confers an odds ratio of 1.2, and 96% power to
detect a dominant allele with a minor allele frequency of 0.1 that
confers an odds ratio of 1.3. For the top three SNPs, we used
Pupasuite PupaSNP (http://pupasuite.bioinfo.cipf.es/) [37] to look
for additional evidence that they may be involved in cancer
aetiology, but found nothing striking. rs2107425 is located in a
region of chromosome 11p15.5 which has no known genes or open
reading frames; but it tags another SNP (rs2251375) with r2 = 1 that
is in a region conserved in mice. rs3817198 is in the lymphocyte-
specific protein 1 (LSP1) gene, also on chromosome 11p15.5, and
also in a region conserved in mice. Loss of heterozygosity in this
region has been found in ovarian, breast, lung, stomach and bladder
cancers, and has been described as a tumour suppressor region in
lung and breast cancers [38–44]. rs9322336 is in intron 2 of ESR1;
no other common variants appear to tag this SNP. ESR1 is a ligand
activated transcription factor, which has been implicated in ovarian
and breast cancer [45,46].
Table 1. All 22 SNPs with significant associations identified using the trend test for association.
Group
Gene
location rs number MAF Controls Cases HetOR{(95% CI) HomOR{ (95% CI) P-het*
Unadjusted
P-trend
Adjusted
P-trend1
BCAC 11p15.5 rs2107425 0.32 1460 2463 0.71 (0.6220.82) 0.88 (0.7021.10) ,0.0001 0.0012 0.0019
OCAC ESR rs9322336 0.23 1453 2464 0.81 (0.7020.93) 0.73 (0.5221.02) 0.005 0.0013 0.0021
BCAC LSP1 rs3817198 0.3 1457 2435 1.16 (1.0121.34) 1.40 (1.1121.75) 0.006 0.0016 0.0026
Cell cycle CDKN1B rs2066827 0.26 1481 2484 0.88 (0.7721.01) 0.68 (0.5120.90) 0.011 0.0035 0.0053
Cell cycle CDK6 rs8 0.21 1473 2481 1.17 (1.0221.35) 1.44 (1.0421.99) 0.015 0.0039 0.0059
Mismatch PMS2 rs7797466 0.18 1305 1968 1.18 (1.0121.38) 1.38 (0.9622.00) 0.039 0.0108 0.0142
Cell cycle CCND1 rs603965 0.44 1476 2464 1.06 (0.9121.23) 1.28 (1.0621.55) 0.027 0.013 0.0178
MMCT-18 RUVBL1 rs13063604 0.22 564 785 1.23 (0.9821.56) 1.54 (1.0022.39) 0.0556 0.016 0.0181
OCAC PGR rs1042838 0.14 1424 2408 1.25 (1.0721.46) 1.09 (0.7321.64) 0.019 0.0161 0.0215
Cell cycle CCND1 rs7178 0.07 1480 2491 1.24 (1.0421.49) 1.24 (0.5023.04) 0.063 0.021 0.0278
OCAC IL18 rs1834481 0.25 1449 2435 0.89 (0.7721.02) 0.77 (0.5921.01) 0.074 0.0227 0.0295
Cell cycle CCND1 rs602652 0.46 1468 2493 1.13 (0.9721.32) 1.24 (1.0321.49) 0.074 0.0235 0.0307
OCAC 11p15.55 SNP1 0.2 1473 2402 0.84 (0.7320.97) 0.86 (0.6021.22) 0.0529 0.0243 0.0314
MMCT-18 CASP5 rs518604 0.44 1041 2029 1.11 (0.9321.33) 1.27 (1.0221.58) 0.0987 0.032 0.0387
Cell cycle CCND1 rs3212879 0.49 1472 2491 0.85 (0.7320.99) 0.82 (0.6820.99) 0.063 0.0321 0.0409
DNA repair XRCC2 rs3218536 0.08 1337 1787 0.88 (0.7221.08) 0.23 (0.0720.79) 0.014 0.0364 0.0439
Cell cycle CCND1 rs3212891 0.46 1475 2476 0.86 (0.7421.00) 0.83 (0.6921.00) 0.082 0.0376 0.0472
Mismatch PMS1 rs256563 0.12 1456 2446 2.50 (0.9926.33) 2.15 (0.8425.48) 0.0435 0.04 0.04
BCAC 8q24.21 rs10808556 0.4 1462 2453 1.15 (0.9921.33) 1.20 (0.9921.46) 0.1071 0.0446 0.0552
Cell cycle CDKN2A rs3731257 0.26 1480 2476 0.89 (0.7821.03) 0.80 (0.6021.07) 0.1345 0.0451 0.056
Cell cycle CCNE1 rs3218036 0.31 1476 2481 1.07 (0.9321.23) 1.27 (1.0121.59) 0.1126 0.0458 0.0567
OCAC 11p15.55 SNP2 0.49 1459 2407 1.20 (1.0221.40) 1.20 (1.0021.44) 0.0611 0.0473 0.0581
{compared with common homozygous.
HetOR – heterozygous odds ratio, HomOR – homozygous odds ratio.
CI – confidence interval.
*P-heterogeneity.
1Adjusted for population stratification.
The P-trend looks for a trend between the OR and the heterozygous (Het); and rare homozygous (Hom) when compared with the common homozygous; the P-
heterogeneity (P-het) does not assume a correlation with increasing number of rare allele.
doi:10.1371/journal.pone.0005983.t001
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Table 2. AML experiment-wise test results for genotyping groups.
Pathway/Group Genes/regions{ No. SNPs
LR P-trend of most
significant SNP* AML P-het* AML P-trend*
Reference with original single
SNP analysis
BCAC{ 5 (51) 16 0.0012 0.0003 0.0028 Song et al. 2009 [19]
OCAC{ 36 (61) 55 0.0014 0.863 0.806 Ramus et al. 2008; [16]; Pearce et al.
2008 [15]; Palmeieri et al. 2008 [17]
MMCT-18 9 63 0.016 0.609 0.468 Quaye et al. in preparation
Cell cycle control 15 101 0.0035 0.274 0.225 DiCioccio et al. 2004 [9]; Song et al.
2006 [11]; Gayther et al. 2007 [14]
Mismatch repair 7 43 0.0106 0.706 0.702 Song et al. 2006 [12]
DNA repair 7 28 0.0374 0.366 0.444 Auranen et al. 2005 [10]; Song et al.
2007 [13]
Ovarian Cancer Oncogenes 5 34 0.0671 0.524 0.528 Quaye et al. 2009 [18]
Total 84 (10) 340 0.051 0.068
*Based on GEOCS, MALOVA and SEARCH genotypes.
{SNPs in regions with no known genes or open reading frames are in parenthesis.
{candidate SNPs validated from the Breast Cancer Association Consortium (BCAC) and Ovarian Cancer Association Consortium (OCAC).
1different SNPs from 8q24.21 were genotyped in both BCAC and OCAC sets; LR – logistic regression; AML – admixture maximum likelihood; het – heterogeneity.
doi:10.1371/journal.pone.0005983.t002
Figure 1. A quantile-quantile (Q-Q) plot of the univariate trend test results. The ordered test statistics are plotted against the expected
statistics given the rank.
doi:10.1371/journal.pone.0005983.g001
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Simple multiple testing correcting methods such as the Bonferroni
or Sidak are too stringent for adjusting the results for the individual
SNPs. Neither of these methods take into account the correlation that
exists between SNPs that tag the genetic variation across gene
regions. Therefore the results reported have not been adjusted for
multiple testing. However, these SNPs may not be significant after
adjusting for multiple testing. We have recently shown that methods
that take into account the totality of the data have greater power to
detect associations [33]. Therefore, we used the AML method to test
the hypothesis that subsets of the SNPs we evaluated, rather than
individual SNPs, were associated with ovarian cancer risk.We did not
find evidence for an overall association between common genetic
variation in the 94 candidate genes or regions and ovarian cancer
risk. However we found evidence of an association for SNPs that had
been identified from breast cancer association studies. This is
intriguing given previous studies that have shown strong genetic
links between breast and ovarian cancer for the highly the penetrant
genes BRCA1 and BRCA2 [3] and recent association studies that
suggest some common variants may be low-penetrance susceptibility
alleles for multiple phenotypes (i.e. pleiotropism). For example SNPs
in a region of chromosome 8q24 appear to be associated with breast,
prostate and ovarian cancer risk [47].
In conclusion, the only significant global association identified
was with the breast cancer associated SNPs. However, providing
definitive evidence that any of these variants represents a true
susceptibility allele is limited by the sample size and consequently
the statistical power to identify risk alleles for which the effect size
is likely to be small. It must also be considered that many
associations are not validated in a second stage study. Genome
wide association studies have successfully identified common risk
alleles for some common cancers, including breast and prostate
cancers [20,48]. In both studies, the sample sizes were much larger
than those used in the current study. These studies also showed
that empirical genome-wide studies represent an efficient ap-
proach to identifying low-penetrance susceptibility alleles, but that
the most significant alleles only confer small relative risks (,1.3). It
will require larger numbers from more extensive multi-centre
collaborations to find ovarian cancer susceptibility alleles that
confer such modest risks. This has recently been achieved with the
development of the ovarian cancer association consortium
(OCAC), which comprises more than 20 ovarian cancer case-
control studies throughout the world [49]; but as the experiences
of the breast and prostate consortia show, common risk alleles for
ovarian cancer are likely to exist and a combination of both
candidate gene and genome wide association studies have the
potential to identify them. However, it has so far proved difficult to
identify highly significant SNPs for ovarian cancer using the
candidate gene approach. GWAS studies of other cancers have
shown that this is likely to prove a more successful approach to
identify low-moderate risk alleles for ovarian cancer in the future.
Supporting Information
Table S1 Genotype frequencies for all SNPs in cases and
controls
Found at: doi:10.1371/journal.pone.0005983.s001 (0.07 MB
XLS)
Table S2 The logistic regression results for all SNPs.
Found at: doi:10.1371/journal.pone.0005983.s002 (0.36 MB
XLS)
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